The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
David Mora, an expert at the Crisis Group analysis center, noted to AFP that due to his lack of direct succession, with his son being held in the United States, El Mencho's death created a power vacuum in the CJNG, with this power vacuum also being a major reason for the escalation in violence, stating "in the absence of a direct succession, a power vacuum is created that opens the door to violent realignments within the organization." Former DEA Chief of International Operations Mike Vigil stated to CBS News that El Mencho's death was prominent and that Mexico could seize on the moment to launch "an effective frontal assault based on intelligence," while also acknowledging that "This is a big opportunity for Mexico and the United States if they work together." El Jardinero would eventually be captured in April 2026. According to Mexican Secretary of the Navy Raymundo Pedro Morales Ángeles, El Jardinero at the time served as “the second in command of the CJNG" and had been "one of the most trusted men (of El Mencho)." However, following El Mencho's death, he also made a major attempt to seize control of the CJNG, mobilizing “personnel, weapons and resources with the aim of taking over the power of the criminal organization.”
The PRIDE (PRoteomics IDEntifications database) is a public data repository of mass spectrometry-based proteomics data, and is maintained by the European Bioinformatics Institute as part of the Proteomics Team. Originally designed by Lennart Martens in 2003 during a stay at the European Bioinformatics Institute as a Marie Curie fellow of the European Commission in the "Quality of Life" Programme (Contract number: QLRI-1999-50595), PRIDE was established as a production service in 2005. The original grant application document from June 2013 to start construction of PRIDE has since been published in a viewpoint article. Several similar proteomics databases have been built, including the GPMDB, PeptideAtlas, Proteinpedia and the NCBI Peptidome. The PRIDE database constitutes a structured data repository, and stores the original experimental data from the researchers without editorial control over the submitted data. In total, PRIDE contains data from about 60 species, the biggest fraction of it coming from human samples (including the data from the two draft human proteomes) followed by the fruit fly Drosophila melanogaster and mouse.
BRD-6929 is a selective inhibitor of HDAC1 and HDAC2, with IC50Tooltip half-maximal inhibitory concentration values of 1 nM and 8–30 nM, respectively, and with 30- to 400-fold selectivity over HDAC3 (IC50 = 398–458 nM) and no inhibition of HDAC8 or class II HDACs (IC50 = >30,000 nM). However, although originally reported to be selective for inhibition of HDAC1 and HDAC2 over HDAC3, subsequent research has found that BRD-6929 is not in fact selective over HDAC3, with previous findings being claimed to have been an assay artifact. As a result, BRD-6929 is no longer recommended as a selective HDAC1 and HDAC2 inhibitor. The drug shows slow-on/slow-off binding kinetics and hence more sustained HDAC inhibition, unlike other HDAC inhibitors like the fast-on/fast-off vorinostat (SAHA) and entinostat (MS-275). Aside from the HDACs, it also showed no binding at 80 other targets at a concentration of 10,000 nM. BRD-6929 produces antidepressant-like and mood-stabilizing-like effects in rodents. This included reducing immobility in the forced swim test (FST) and attenuating amphetamine-induced hyperlocomotion without affecting basal locomotor activity. Conversely, vorinostat was ineffective in these tests. In addition, vorinostat showed dissimilar and lesser effects on gene transcription compared to BRD-6929. These differences may be related to selectivity and duration of exposure, with sustained exposure as with BRD-6929 possibly being advantageous.
=== November === 1 November – A Wellington College student is diagnosed with measles, bringing the total number of measles cases nationwide to 14. 2 November – A new measles case is reported in Auckland, bringing the total number of cases nationwide to 17. 3 November – The New Zealand Government launches a three-month visa waiver trial for Chinese citizens with valid Australian visitor, work, family or student visas. 4 November – 400 protesters gather on the grounds of the New Zealand Parliament to protest against the Government's proposed legislation easing restrictions of gene technology. New Zealand First leader Winston Peters and Green Party MP Scott Willis address the crowd, reiterating their opposition to the legislation. 5 November: 20,000 secondary school teachers affiliated with the Post Primary Teachers' Association hold a half-day strike to demand better pay and work conditions. Australian mining company Santana Minerals secures a 30-year permit from the New Zealand Government to mine gold from the Bendigo-Ophir goldfields. The New Zealand Parliament passes legislation formalizing a Treaty of Waitangi settlement with Ngāti Pāoa. The settlement includes NZ$23.5 million in financial compensation, recognising 12 "culturally significant" sites, and a formal Crown apology for historical land alienation. 6 November: Former Deputy Police Commissioner Jevon McSkimming pleads guilty to three charges of possessing child sexual exploitation and bestiality material.
Sources: en.wikipedia.org
During examinations of the head and torso, this scattered radiation can spread throughout the body and is difficult to shield with radiation protective clothing. Fears that a lead apron will prevent radiation from leaving the body are unfounded, however, because lead absorbs radiation rather than scattering it. When preparing an orthopantomogram (OPG) for a dental overview radiograph, it is sometimes recommended not to wear a lead apron, as it does little to shield scattered radiation from the jaw area, but may hinder the rotation of the imaging device. However, according to the 2018 X-ray regulation, it is still mandatory to wear a lead apron when taking an OPG.
== Achievements == George Kenner contributed to many areas of organic chemistry. In the 1960s, George Kenner, R.A. Gregory and Hilda Tracy were involved in the seminal discovery and synthesis of the peptide hormone gastrin at the University of Liverpool. Gastrin is involved in secretion of gastric acid (HCl) in the stomach. The first chemical synthesis of a lysozyme-like enzyme of 129 amino acids using the classical approach was attempted by Kenner and his group at the University of Liverpool in the 1970s. This would have been the largest protein molecule synthesised in a laboratory using classical peptide synthesis up to that time. He carefully planned a convergent synthesis of this lysozyme analogue, containing 129 amino acid residues joined in a rigorously defined order. The efforts of Kenner and his group led to the synthesis of the 129 amino acid peptide chain in protected form. But the dream of making a wholly synthetic lysozyme enzyme was only achieved 30 years later, in 2007. This synthesis of functionally active lysozyme was achieved by a single individual, Thomas Durek, working in Steve B. Kent's group at the University of Chicago. The value of George Kenner's contributions to the methodology of peptide chemistry had profound influence on developments in many biomedicine fields. For example it led to the synthesis of antigens of defined geometry for immunological studies.
== Mechanism == Biochemical and structural analyses of aminopeptidase (APPro), methionine aminopeptidase (MetAP), and prolidase, all members of the "pita-bread" metalloenzymes, suggest that they share a common mechanism scheme. The main difference arises in the location of the carbonyl oxygen atom of the scissile peptide bond.
=== Senior team === Townsend's first call-up to the senior England squad came in September 2013, for the World Cup qualifiers against Moldova and Ukraine. He made his senior debut against Montenegro in a World Cup qualifier on 11 October, during which he scored the third goal of a 4–1 win with a "low swerving finish" from outside the penalty area after 78 minutes, two minutes before being substituted, and was named man of the match. He earned a second cap four days later against Poland, playing almost all of the 2–0 home win. A second England goal came in the Euro 2016 qualification campaign in a 5–0 win over San Marino on 9 October 2014, as he came on for the final third of the match. His next appearance marked his third England goal; on 31 March 2015 he scored the equaliser in the 79th minute against Italy, having come on seven minutes earlier in a friendly match which ended 1–1. The 20-yard strike was described as a "sweet right-foot drive into the bottom corner"; Townsend took to Twitter immediately after the match to respond to Paul Merson after he had said Townsend's club form did not justify him being in the England team.
With the fall of Babylon to the rising Achaemenid Persian Empire, king Cyrus the Great issued a proclamation known as the Edict of Cyrus, encouraging the exiles to return to their homeland after the Persians raised it as an autonomous Jewish-governed province named Yehud. Under the Persians (c. 539–332 BCE), the returned Jewish population restored the city and rebuilt the Temple in Jerusalem. The Cyrus Cylinder is controversially cited as evidence for Cyrus allowing the Judeans to return. The returnees showed a "heightened sense" of their ethnic identity and shunned exogamy, which was treated as a "permissive reality" in Babylon. Circumcision was no longer a significant ethnic marker, with increased emphasis on genealogical descent or faith in Yahweh. Jason A. Staples argues that the majority of contemporary Jews, regardless of theology, wished for the reunion of northern Israelites and southern Jews and did not completely appropriate the Israel identity for themselves.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.